RE:RE:Finally listened to the CC As to your second point, I am using a very conservative revenue multiplier.
I would actually agree with you that TH should attract higher than the 5-8x peak sales that other biotechs get due to its structure.
Lots of moving parts but just illustrating that there is plenty of upside left.
bfw
Wino115 wrote: "EGRIFTA is the higher margin drug" -- on what basis are you estimating this? Just curious as the salesforce sells both, there was capitalized R&D (I'm guessing) that is depreciated and there's no R&D on Trogarzo, just sales/marketing costs and the Taimed payments. It just seems that at volume levels, Trogarzo should have a higher margin. What do I have wrong there? I was also assuming in my Financial Metrics that there may be a higher multiple to get valuation at peak higher because it should have higher margins and free cash flow than your average biotech given cost structure as a marketing arm essentially. Thanks, and undertand this is all pie-in-the-sky depending on proper execution.